These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32798651)

  • 41. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
    Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
    Gao H; Marhefka C; Jacobs MD; Cao J; Bandarage UK; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2616-2621. PubMed ID: 29945794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and characterization of novel allosteric FAK inhibitors.
    Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
    Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
    Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and optimization of pyrazole amides as antagonists of CCR1.
    Harcken C; Sarko C; Mao C; Lord J; Raudenbush B; Razavi H; Liu P; Swinamer A; Disalvo D; Lee T; Lin S; Kukulka A; Grbic H; Patel M; Patel M; Fletcher K; Joseph D; White D; Amodeo L; Berg K; Brown M; Thomson DS
    Bioorg Med Chem Lett; 2019 Feb; 29(3):435-440. PubMed ID: 30455146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1
    Oh Y; Jang M; Cho H; Yang S; Im D; Moon H; Hah JM
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):372-376. PubMed ID: 31856610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
    J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
    Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.
    Lovering F; Morgan P; Allais C; Aulabaugh A; Brodfuehrer J; Chang J; Coe J; Ding W; Dowty H; Fleming M; Frisbie R; Guzova J; Hepworth D; Jasti J; Kortum S; Kurumbail R; Mohan S; Papaioannou N; Strohbach JW; Vincent F; Lee K; Zapf CW
    Eur J Med Chem; 2018 Feb; 145():606-621. PubMed ID: 29348070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
    Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors.
    Ma S; Wang L; Ouyang B; Fan M; Qi J; Yao L
    Bioorg Med Chem; 2020 Oct; 28(19):115683. PubMed ID: 32912437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.
    Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Fransen S; Vanormelingen J; Stassen JM; Leysen D; Defert O
    J Med Chem; 2015 May; 58(10):4309-24. PubMed ID: 25898023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
    Kast R; Schirok H; Figueroa-Pérez S; Mittendorf J; Gnoth MJ; Apeler H; Lenz J; Franz JK; Knorr A; Hütter J; Lobell M; Zimmermann K; Münter K; Augstein KH; Ehmke H; Stasch JP
    Br J Pharmacol; 2007 Dec; 152(7):1070-80. PubMed ID: 17934515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).
    Li L; Liu F; Jin N; Tang S; Chen Z; Yang X; Ding J; Geng M; Jiang L; Huang M; Cao J
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2600-4. PubMed ID: 27106711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chroman-3-amides as potent Rho kinase inhibitors.
    Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.
    Andrews PD; Becroft M; Aspegren A; Gilmour J; James MJ; McRae S; Kime R; Allcock RW; Abraham A; Jiang Z; Strehl R; Mountford JC; Milligan G; Houslay MD; Adams DR; Frearson JA
    Biochem J; 2010 Nov; 432(1):21-33. PubMed ID: 20854259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.